Arcutis Biotherapeutics (ARQT) Debt to Equity: 2021-2025
Historic Debt to Equity for Arcutis Biotherapeutics (ARQT) over the last 4 years, with Sep 2025 value amounting to $0.69.
- Arcutis Biotherapeutics' Debt to Equity fell 47.45% to $0.69 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.69, marking a year-over-year decrease of 47.45%. This contributed to the annual value of $0.68 for FY2024, which is 70.10% down from last year.
- Per Arcutis Biotherapeutics' latest filing, its Debt to Equity stood at $0.69 for Q3 2025, which was down 11.72% from $0.78 recorded in Q2 2025.
- Over the past 5 years, Arcutis Biotherapeutics' Debt to Equity peaked at $4.30 during Q3 2023, and registered a low of $0.24 during Q4 2021.
- Its 3-year average for Debt to Equity is $1.52, with a median of $1.09 in 2024.
- Per our database at Business Quant, Arcutis Biotherapeutics' Debt to Equity skyrocketed by 562.87% in 2023 and then crashed by 70.10% in 2024.
- Arcutis Biotherapeutics' Debt to Equity (Quarterly) stood at $0.24 in 2021, then spiked by 288.25% to $0.94 in 2022, then skyrocketed by 141.19% to $2.28 in 2023, then crashed by 70.10% to $0.68 in 2024, then crashed by 47.45% to $0.69 in 2025.
- Its Debt to Equity was $0.69 in Q3 2025, compared to $0.78 in Q2 2025 and $0.75 in Q1 2025.